Trial intelligence / Profile preview

Rotigotine in advanced Parkinson's disease (SP715)

NCT00594386Phase 3Completed

Sponsor
UCB
Start
Aug 2002
Primary completion
Dec 2008
Modality
Small Molecules
Countries
2
01

Overview

Phase 3, open-label, single-arm trial of rotigotine in Parkinson's disease (PD), sponsored by UCB. Primary endpoint: Number of Subjects With at Least One Adverse Event at 6 years. Started Aug 2002; status: completed.

02

Drugs

rotigotine
03

Conditions

Parkinson's disease (PD)

Beyond the preview

Go deeper on NCT00594386.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00594386.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call